New Partnership Aims to Advance Alzheimer's and CTE Diagnostics

Partnering with Hall of Fame Health, CereMark Pharma, a clinical-stage radiopharmaceutical business, will assist the latter's Phase 3 clinical studies of its innovative diagnostic radiopharmaceutical, F-18 Flornaptitril. The two main pathogenic proteins implicated in Alzheimer's disease and chronic traumatic encephalopathy are the targets of the PET imaging agent. The Phase 3 study is anticipated to start in 2024, later this year.

CEO of CereMark Pharma, Dr. Henry 'Hank' Chilton, is certain that this collaboration will offer accurate insights on cognitive health, including Alzheimer's disease and chronic traumatic encephalopathy, to patients, their families, and the medical community. Additionally, by increasing knowledge of neurodegenerative disorders, the alliance will assist improve care for individuals who are affected.

There is currently no FDA-approved radiopharmaceutical that can determine if people with MCI may have more neurodegeneration. This may result in increased confidence when making decisions about the most effective ways to treat these terminal illnesses.

In response to concerns raised by Pro Football Hall of Famers who saw their colleagues struggle with healthcare, Hall of Fame Health was founded. It currently seeks to establish a national network of hospitals, health systems, and behavioural health specialists with a focus on mental health, drug addiction, and crisis management for former NFL players, veterans of the armed forces, and their families. The group intends to grow to include athletic departments, collegiate conferences, other sports, and veteran communities. It has already forged partnerships with veteran and collegiate alumni groups.